Zandelisib not checked
Kyowa Kirin Co., Ltd. · MEI Pharma, Inc. · ME-401
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Blocks PI3K, an enzyme that passes growth signals inside cells. Mostly used against cancer.-lisib: PI3K inhibitors WHO name stem
- How it’s given
- “In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).”In the company’s words, NCT04533581 on ClinicalTrials.gov
- Tested for
- Indolent B-cell Non-Hodgkin's Lymphoma
- Main trialPhase 2
- “The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.”In the company’s words, NCT04533581 on ClinicalTrials.gov
- Other names
- ME-401
Coming up1
- 31 May 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 May 2028 | Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL) | |
| Phase 3Terminated | 20 Mar 2023 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | |
| Phase 2Withdrawn | 15 Mar 2023 | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL | |
| Phase 2Terminated | 24 Mar 2023 | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) | |
| Phase 1Terminated | 29 Mar 2023 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | |
| Phase 1Completed | 15 Jan 2025 | Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026